Literature DB >> 15058585

Determination of midazolam and its metabolite as a probe for cytochrome P450 3A4 phenotype by liquid chromatography-mass spectrometry.

Hideko Kanazawa1, Akiko Okada, Eri Igarashi, Megumu Higaki, Takako Miyabe, Tadashi Sano, Ryouhei Nishimura.   

Abstract

This study demonstrated the analysis of midazolam and its metabolites by liquid chromatography-mass spectrometry (LC-MS) with a sonic spray ionization (SSI) interface. The analytical column was a YMC-Pak Pro C18 (50 mm x 2.0 mm i.d.) using 10 mM ammonium acetate (pH 4.8)-methanol (1:1) at a flow rate of 0.2 ml min(-1). The drift voltage was 100 V. The sampling aperture was heated at 110 degrees C and the shield temperature was 230 degrees C. The lower limits for the detection of midazolam and 1'-hydroxymidazolam were 26.3 and 112.76 pg injected, respectively. The calibration curves for midazolam and 1'-hydroxymidazolam were linear in the range of 0.1-5 microg ml(-1). Within-day relative standard deviations was less than 7%. The method was applied to the determination of midazolam in monkey plasma, and the analysis of midazolam and its metabolites in an in vitro study with recombinant cytochrome P450 (CYP) 3A4. This method is sufficiently sensitive and useful to elucidate the kinetics of midazolam metabolite formation. We also investigated the effect of propofol on the metabolism of midazolam using recombinant CYP3A4. Propofol competitively inhibited the metabolism of midazolam to 1'-hydroxymidazolam by CYP3A4.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15058585     DOI: 10.1016/j.chroma.2003.12.039

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  10 in total

1.  A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors.

Authors:  Hanna K Sanoff; Janine M Davies; Christine Walko; William Irvin; Larry Buie; Kimberly Keller; Anastasia Ivanova; Wing-Keung Chiu; Bert H O'Neil; Thomas E Stinchcombe; E Claire Dees
Journal:  Invest New Drugs       Date:  2010-04-13       Impact factor: 3.850

Review 2.  Investigating metabolite-protein interactions: an overview of available techniques.

Authors:  Grace Xiaolu Yang; Xiyan Li; Michael Snyder
Journal:  Methods       Date:  2012-06-28       Impact factor: 3.608

3.  Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease.

Authors:  Fabrizio d'Esposito; Noelia Nebot; Robert J Edwards; Michael Murray
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

4.  Phase I trial of vinflunine and pemetrexed in refractory solid tumors.

Authors:  Hanna K Sanoff; Janine Davies; Christine Walko; Larry Buie; Wing-Keung Chiu; Anastasia Ivanova; Bert O'Neil; Thomas E Stinchcombe; Kimberly Keller; E Claire Dees
Journal:  Invest New Drugs       Date:  2009-10-15       Impact factor: 3.850

5.  CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients.

Authors:  Wei Zhang; Yan-Zi Chang; Quan-Cheng Kan; Li-Rong Zhang; Zhi-Song Li; Hui Lu; Zhong-Yu Wang; Qin-Jun Chu; Jie Zhang
Journal:  Eur J Clin Pharmacol       Date:  2009-09-26       Impact factor: 2.953

6.  In vitro and in vivo evaluation of the inhibition potential of risperidone toward clozapine biotransformation.

Authors:  Manoranjenni Chetty; Fabrizio d'Esposito; Wei V Zhang; John Glen; Glenys Dore; Zvijezdana Stankovic; Robert J Edwards; Iqbal Ramzan; Michael Murray
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

7.  Inhibition of hepatic cytochrome P450 enzymes and sodium/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity.

Authors:  Lei-lei Ma; Zhi-tao Wu; Le Wang; Xue-feng Zhang; Jing Wang; Chen Chen; Xuan Ni; Yun-fei Lin; Yi-yi Cao; Yang Luan; Guo-yu Pan
Journal:  Acta Pharmacol Sin       Date:  2016-01-25       Impact factor: 6.150

8.  Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans.

Authors:  Ngoc Ngo; Zhixia Yan; Tyler N Graf; Daniel R Carrizosa; Angela D M Kashuba; E Claire Dees; Nicholas H Oberlies; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2008-12-29       Impact factor: 3.922

9.  N-alkylprotoporphyrin formation and hepatic porphyria in dogs after administration of a new antiepileptic drug candidate: mechanism and species specificity.

Authors:  Jean-Marie Nicolas; Hugues Chanteux; Valérie Mancel; Guy-Marie Dubin; Brigitte Gerin; Ludovicus Staelens; Olympe Depelchin; Sophie Kervyn
Journal:  Toxicol Sci       Date:  2014-06-27       Impact factor: 4.849

10.  Effect of Pregnane X Receptor*1B genetic polymorphisms on postoperative analgesia with fentanyl in Chinese patients undergoing gynecological surgery.

Authors:  Jing-Jing Yuan; Xiao-Jing Ma; Zhi-Song Li; Yan-Zi Chang; Wei Zhang; Quan-Cheng Kan; Jun-Kai Hou; Li-Rong Zhang
Journal:  BMC Med Genet       Date:  2016-11-23       Impact factor: 2.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.